Zynerba Pharmaceuticals, Inc.

LSE:0M40 Stock Report

Market Cap: US$65.6m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Zynerba Pharmaceuticals Valuation

Is 0M40 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0M40 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$56.32
Fair Value
97.7% undervalued intrinsic discount
2
Number of Analysts

Below Fair Value: 0M40 ($1.31) is trading below our estimate of fair value ($56.32)

Significantly Below Fair Value: 0M40 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0M40?

Key metric: As 0M40 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0M40. This is calculated by dividing 0M40's market cap by their current book value.
What is 0M40's PB Ratio?
PB Ratio2.3x
BookUS$29.02m
Market CapUS$65.60m

Price to Book Ratio vs Peers

How does 0M40's PB Ratio compare to its peers?

The above table shows the PB ratio for 0M40 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average11x
REDX Redx Pharma
17.4x-22.3%UK£58.3m
EAH ECO Animal Health Group
0.5x39.2%UK£42.3m
FUM Futura Medical
12.3x188.3%UK£97.3m
SAR Sareum Holdings
13.6xn/aUK£28.1m
0M40 Zynerba Pharmaceuticals
2.3x67.2%US$65.6m

Price-To-Book vs Peers: 0M40 is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (12.8x).

Price to Book Ratio vs Industry

How does 0M40's PB Ratio compare vs other companies in the GB Pharmaceuticals Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.5x39.2%US$51.82m
OCTP Oxford Cannabinoid Technologies Holdings
0.6x15.1%US$1.60m
NFX Nuformix
0.1xn/aUS$626.57k
No more companies available in this PB range
0M40 2.3xIndustry Avg. 2.3xNo. of Companies3PB03.67.210.814.418+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0M40 is good value based on its Price-To-Book Ratio (2.3x) compared to the UK Pharmaceuticals industry average (2.7x).

Price to Book Ratio vs Fair Ratio

What is 0M40's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0M40 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0M40's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0M40 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jan ’26n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Dec ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Nov ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Oct ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Sep ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Aug ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jul ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jun ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
May ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Apr ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Mar ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Feb ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jan ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Dec ’24n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Nov ’24n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Oct ’24US$1.27
US$1.26
-1.0%
11.6%US$1.40US$1.11n/a2
Sep ’24US$1.32
US$1.26
-4.9%
11.6%US$1.40US$1.11n/a2
Aug ’24US$0.37
US$5.80
+1,473.9%
69.1%US$10.00US$0.40n/a3
Jul ’24n/a
US$5.80
0%
69.1%US$10.00US$0.40n/a3
Jun ’24US$0.34
US$5.10
+1,412.5%
72.1%US$10.00US$0.40n/a4
May ’24US$0.38
US$5.38
+1,313.4%
74.2%US$11.00US$0.50n/a4
Apr ’24US$0.43
US$5.38
+1,148.8%
74.2%US$11.00US$0.50n/a4
Mar ’24US$0.49
US$5.44
+999.2%
71.9%US$11.00US$0.76n/a4
Feb ’24US$0.57
US$5.44
+846.6%
71.9%US$11.00US$0.76n/a4
Jan ’24US$0.53
US$5.44
+936.2%
71.9%US$11.00US$0.76n/a4
Analyst Price Target
Consensus Narrative from 2 Analysts
US$1.26
Fair Value
3.6% overvalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/12 18:40
End of Day Share Price 2023/10/10 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zynerba Pharmaceuticals, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Corey DavisCanaccord Genuity
Elemer PirosCantor Fitzgerald & Co.
Oren LivnatH.C. Wainwright & Co.